Last reviewed · How we verify
JY09
At a glance
| Generic name | JY09 |
|---|---|
| Also known as | Placebo |
| Sponsor | Beijing Dongfang Biotech Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Placebo in T2DM Patients (PHASE3)
- A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin (PHASE3)
- Influence of JY09 on Pharmacokinetics of Metformin , Rosuvastatin , and Digoxin and the QT Interval Study in Overweight Chinese Subjects (PHASE1)
- Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of JY09 (PHASE1)
- a Study of JY09 in Chinese Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JY09 CI brief — competitive landscape report
- JY09 updates RSS · CI watch RSS
- Beijing Dongfang Biotech Co., Ltd. portfolio CI